Related Experiment Video
Updated: Feb 13, 2026

Immunohistochemistry and Multiple Labeling with Antibodies from the Same Host Species to Study Adult Hippocampal Neurogenesis
Published on: April 22, 2015
Pharmacokinetics and tolerability of cinitapride in healthy Chinese volunteers: a randomized, open-label, single- and
Xiong Zhang1, Ying Wang2, Junlin Cheng1
1a Department of Clinical Pharmacology Lab , Nanjing First Hospital, Nanjing Medical University , Nanjing , Jiangsu , China.
Abstract:
Cinitapride (CIN) is a drug for functional dyspepsia. The purpose of the study was to investigate the pharmacokinetics and tolerability of CIN in healthy Chinese volunteers. A randomized, open-label, single- and multiple-dose study was conducted in 12 healthy volunteers. Three different doses of CIN (1, 2, 4 tablets) were given to six groups in the single-dose study, and one tablet (1 mg) of CIN was administered three times a day in the multiple-dose study. Blood samples were collected at predetermined time intervals after CIN dosing and analyzed by LC-MS/MS. Eleven volunteers completed the study. After single dose, the Cmax and AUC of plasma increased approximately linearly with dosage; no statistically significant differences were found in pharmacokinetic parameters between three dose groups. After multiple doses, there was no significant change in Tmax and t1/2 compared with the results from the single dose. After repeated doses, AUC0-t and AUC0-∞ were increased, while CLz/F slightly decreased. And no differences between male and female. The pharmacokinetic parameters of this study were consistent with study results of non-Chinese subjects. Good tolerability was demonstrated in both single- and multiple-dose studies with dosage range from 1 to 4 mg in healthy Chinese subjects.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Pharmacokinetic–Pharmacodynamic Relationship: Intensity of Dose-Effect Relationship
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

